Lung cancer is the leading cause for cancer-related deaths in Canada. There is evidence that early detection of lung cancer with low-dose computed tomography (LDCT) can reduce lung cancer mortality. The purpose of this program is to outline existing guidance on lung cancer screening with LDCT for primary care physicians in Canada. This program will also highlight the mortality benefits of diagnosing lung cancer at an early stage and discuss key strategies for patient engagement in the family medicine practice.
This program has received financial support from AstraZeneca in the form of an unrestricted educational grant.